Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216560 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of 7MW4911 in GI Cancer
A Phase 1 study of GI Cancers, sponsored by Mabwell (Shanghai) Bioscience Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT07216560: Recruiting Phase 1 study of GI Cancers, sponsored by Mabwell (Shanghai) Bioscience Co..
NCT07216560 is a Phase 1 study of GI Cancers that is actively recruiting participants, run by Mabwell (Shanghai) Bioscience Co.. The registered enrollment target is 200 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (233% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216560, a Phase 1 study of GI Cancers, is actively recruiting participants, sponsored by Mabwell (Shanghai) Bioscience Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.
Primary Outcome
To assess the safety and tolerability of 7MW4911 in patients with advanced colorectal cancer and other advanced gastrointestinal tumors
Conditions Studied
Interventions
- DRUG 7MW4911
Study Locations (4)
Florida
- Hematology Oncology Associates of the Treasure Coast - Port Saint Lucie
New York
- START - Long Island City
Utah
- START Moutain Region - West Valley City
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT07216560 shows while recruiting
NCT07216560 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (233% higher).
The record links to 1 condition, with GI Cancers appearing as the primary indexed condition, and to 1 intervention - of which 7MW4911 is the first listed.
NCT07216560 reports a single indexed study location in Florida, New York, Utah.
Frequently Asked Questions
What is clinical trial NCT07216560 about?
NCT07216560 is a clinical study titled "First-in-human Study of 7MW4911 in GI Cancer". This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.
What is the current status of trial NCT07216560?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2026-01-13. Estimated completion is 2028-12.
What conditions does trial NCT07216560 study?
This clinical trial studies the following conditions: GI Cancers.
What interventions are being tested in trial NCT07216560?
The interventions under investigation include: 7MW4911 (DRUG).
Who is sponsoring clinical trial NCT07216560?
This trial is sponsored by Mabwell (Shanghai) Bioscience Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216560 being conducted?
This trial has 4 study locations across Florida, New York, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07216560's enrollment target sits among peer trials
200 260th of 2000 higher than 1,724 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI